In conclusion , polyphenols can successfully reduce HbA1c in T2DM without any intervention at glycemia , and could contribute to the prevention of diabetes complications
ABSTRACT Polyphenols have been extensively studied for their antioxidant and anti-inflammatory properties .
Recently , their antiglycative actions by oxidative stress modulation have been linked to the prevention of diabetes and associated complications .
This article assesses the evidence for polyphenol interventions on glycohemoglobin ( HbA1c ) in non-diabetic , pre-diabetic , and type 2 diabetes mellitus ( T2DM ) subjects .
Chronic Ingestion of Flavan-3-ols and Isoflavones Improves Insulin Sensitivity and Lipoprotein Status and Attenuates Estimated 10-Year CVD Risk in Medicated Postmenopausal Women With Type 2 Diabetes
OBJECTIVE To assess the effect of dietary flavonoids on cardiovascular disease ( CVD ) risk in postmenopausal women with type 2 diabetes on established statin and hypoglycemic therapy . RESEARCH DESIGN AND METHODS Despite being medicated , patients with type 2 diabetes have elevated CVD risk , particularly postmenopausal women . Although dietary flavonoids have been shown to reduce CVD risk factors in healthy participants , no long-term trials have examined the additional benefits of flavonoids to CVD risk in medicated postmenopausal women with type 2 diabetes . We conducted a parallel- design , placebo-controlled trial with type 2 diabetic patients r and omized to consume 27 g/day ( split dose ) flavonoid-enriched chocolate ( containing 850 mg flavan-3-ols [ 90 mg epicatechin ] and 100 mg isoflavones [ aglycone equivalents)]/day ) or matched placebo for 1 year . RESULTS Ninety-three patients completed the trial , and adherence was high ( flavonoid 91.3 % ; placebo 91.6 % ) . Compared with the placebo group , the combined flavonoid intervention result ed in a significant reduction in estimated peripheral insulin resistance ( homeostasis model assessment of insulin resistance [ HOMA-IR ] −0.3 ± 0.2 ; P = 0.004 ) and improvement in insulin sensitivity ( quantitative insulin sensitivity index [ QUICKI ] 0.003 ± 0.00 ; P = 0.04 ) as a result of a significant decrease in insulin levels ( −0.8 ± 0.5 mU/L ; P = 0.02 ) . Significant reductions in total cholesterol : HDL-cholesterol ( HDL-C ) ratio ( −0.2 ± 0.1 ; P = 0.01 ) and LDL-cholesterol ( LDL-C ) ( −0.1 ± 0.1 mmol/L ; P = 0.04 ) were also observed . Estimated 10-year total coronary heart disease risk ( derived from UK Prospect i ve Diabetes Study algorithm ) was attenuated after flavonoid intervention ( flavonoid + 0.1 ± 0.3 vs. placebo 1.1 ± 0.3 ; P = 0.02 ) . No effect on blood pressure , HbA1c , or glucose was observed . CONCLUSIONS One-year intervention with flavan-3-ols and isoflavones improved biomarkers of CVD risk , highlighting the additional benefit of flavonoids to st and ard drug therapy in managing CVD risk in postmenopausal type 2 diabetic patients
In conclusion , polyphenols can successfully reduce HbA1c in T2DM without any intervention at glycemia , and could contribute to the prevention of diabetes complications
ABSTRACT Polyphenols have been extensively studied for their antioxidant and anti-inflammatory properties .
Recently , their antiglycative actions by oxidative stress modulation have been linked to the prevention of diabetes and associated complications .
This article assesses the evidence for polyphenol interventions on glycohemoglobin ( HbA1c ) in non-diabetic , pre-diabetic , and type 2 diabetes mellitus ( T2DM ) subjects .